The year 2026 has crowned Tirzepatide the undisputed champion of metabolic medicine. This dual GLP-1/GIP receptor agonist, sold as Mounjaro for diabetes and Zepbound for weight management, now routinely delivers 22–27 % total body-weight loss in real-world registries, with the newly launched oral tablet eliminating needles entirely while retaining 94 % of the injectable’s power. […]